• The FDA should see a favorable benefit-to-risk ratio for KALYDECO in children of ages 2-5.
• Positive Phase 3 trials in patients with the most common CF mutation should also be enough for approval. This will triple the current addressable CF market. Continue reading Vertex Should Expect Approvals For Its Cystic Fibrosis Medications
In his first weekly column for Cystic Fibrosis News Today, PhD. student and CF patient Stephen Shannon talks candidly about what the ongoing search for a cure for Cystic Fibrosis means to him, and why there is great reason for Hope.
I was two years old when I was diagnosed with Cystic Fibrosis (CF). It has taken me twenty-five years to come to terms with the disease. I’ve spent the greater part of my life trying to convince Continue reading An Undeniable Hope: Recent CF Breakthroughs Show That a Cure Can Be Found
JUDY WOODRUFF: The president laid out a plan for a new biomedical research initiative today, one aimed at finding targeted treatments for individuals. It’s called precision medicine, or more frequently referred to as personalized medicine. Continue reading A push to use the human genome to make medicine more precise–Transcript
State Will Revise Eligibility Criteria for Renewing Prescriptions for Vertex Pharmaceuticals’ Kalydeco
JOSEPH WALKER, Feb. 5, 2015 1:49 p.m. ET
Arkansas Medicaid officials have reached a legal settlement to resolve claims the state denied patients an expensive cystic fibrosis therapy made by Vertex Pharmaceuticals Inc. because of its Continue reading Arkansas Reaches Settlement in Cystic Fibrosis Drug Suit
Dear Healthcare Provider,
We would like to inform you that Gilead Sciences, Inc. and Cystic Fibrosis Services, Inc. (CFS) have mutually agreed that CFS will transition out of the network of pharmacies for Cayston®(aztreonam for inhalation solution). Gilead and CFS are collaborating on a transition Continue reading CFS Will Transition Cayston Therapy to Other Pharmacies
Protalix BioTherapeutics, Inc., an Israeli pharmaceutical company known for its proprietary, US Food and Drug Administration-approved, plant-based enzyme taliglucerase alfa for Gaucher disease, recently announced their new company strategy for accelerated growth. The Company has Continue reading Protalix Announces Strategy for Novel CF Drug AIR DNase for Recurrent Respiratory Infections
If someone you love has been diagnosed with a rare disease you want the best treatment and the best doctors and sometimes treatment is on going and that can mean clinical trials.
“The floor dropped out from underneath us, it was devastating devastating,” said Tara Halvax. Continue reading Clinical Trials Can Sometimes Be Best Treatment for Cystic Fibrosis
Cayston (aztreonam for inhalation solution) Availability 2015
On December 22nd, Gilead sent out a “Dear Healthcare Provider” announcement that they and Cystic Fibrosis Services, Inc. (CFS) Walgreens have mutually agreed that CFS will transition out of the network of pharmacies providing Cayston.
Foundation Care Pharmacy is currently a provider of Cayston (aztreonam for inhalation solution) /Altera nebulizer to CF patients nationwide. They would like the opportunity to assist you in using Cayston.
Foundation Care provides pharmacy services to over 6,000 cystic fibrosis patients nationwide. They have been providing Cayston and support for the Altera device since the product was launched in 2010. They offer full retail pharmacy services and will meet all of your pharmacy needs. Foundation Care will:
Contact CF patients pharmacy, transfer their Cayston prescriptions, perform reimbursement, prior authorization, fulfillment and dispensing services, offer free home delivery of Cayston via Fed Ex next day service, and provide compliance and adherence services to patients, including refill reminders.
In addition, patients receiving Cayston from Foundation Care will also receive at no cost:
• A Nebulizer Cleaning Kit
• Their choice of either: Vitamin D3 (Replesta), Hypertonic Saline or ChoiceFul Vitamins
Anthera Pharmaceuticals, Inc., a biopharmaceutical company that specializes in research and development of novel treatments for serious and fatal diseases such as lupus, lupus with nephrotic affectation, and exocrine pancreatic insufficiency (EPI) secondary to cystic fibrosis Continue reading Anthera, Patheon to Co-Manufacture Sollpura for CF Phase 3 Trial